Meitheal Pharmaceuticals is a fully integrated biopharmaceutical company that focuses on addressing unmet needs in the biopharma industry through the development and commercialization of innovative products. The company has recently ventured into the biosimilars market with the acquisition of YUSIMRY®, highlighting its commitment to providing impactful healthcare solutions. Meitheal's product pipeline includes a range of biosimilars for oncology, diabetes, and fertility, as well as generics and biologics. The company emphasizes affordability and accessibility, aiming to deliver critical medicines to patients while maintaining a robust manufacturing and supply chain.

In addition to its product offerings, Meitheal is dedicated to sustainability and fostering a collaborative work environment, reflecting the Irish tradition of "meitheal," which means working together for the greater good. The company values diversity, integrity, and transparency, creating a culture that encourages employee growth and recognition. Meitheal's strategic partnerships with global entities further enhance its ability to bring innovative therapies to market, ensuring that healthcare solutions remain within reach for those in need.

United States

Founded in 2017, Meitheal Pharmaceuticals is a privately owned pharmaceutical company focusing on generic injectable products.  Headquartered near Chicago, Illinois, Meitheal has an established management team and an aggressive growth strategy.  Through global partnerships, our goal is to bring supply to US healthcare providers that demand a reliable, high quality, yet affordable supply of injectables.

Meitheal

Company Details